全文获取类型
收费全文 | 3009篇 |
免费 | 196篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 76篇 |
妇产科学 | 78篇 |
基础医学 | 399篇 |
口腔科学 | 9篇 |
临床医学 | 294篇 |
内科学 | 666篇 |
皮肤病学 | 60篇 |
神经病学 | 356篇 |
特种医学 | 54篇 |
外科学 | 243篇 |
综合类 | 12篇 |
一般理论 | 8篇 |
预防医学 | 353篇 |
眼科学 | 27篇 |
药学 | 221篇 |
中国医学 | 8篇 |
肿瘤学 | 334篇 |
出版年
2023年 | 38篇 |
2022年 | 53篇 |
2021年 | 136篇 |
2020年 | 75篇 |
2019年 | 128篇 |
2018年 | 139篇 |
2017年 | 71篇 |
2016年 | 94篇 |
2015年 | 114篇 |
2014年 | 146篇 |
2013年 | 186篇 |
2012年 | 313篇 |
2011年 | 312篇 |
2010年 | 151篇 |
2009年 | 128篇 |
2008年 | 172篇 |
2007年 | 185篇 |
2006年 | 161篇 |
2005年 | 126篇 |
2004年 | 119篇 |
2003年 | 88篇 |
2002年 | 93篇 |
2001年 | 19篇 |
2000年 | 17篇 |
1999年 | 21篇 |
1998年 | 13篇 |
1997年 | 5篇 |
1996年 | 9篇 |
1995年 | 7篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 9篇 |
1991年 | 13篇 |
1990年 | 10篇 |
1989年 | 11篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1976年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 4篇 |
1967年 | 1篇 |
1966年 | 1篇 |
1948年 | 4篇 |
1943年 | 1篇 |
1924年 | 1篇 |
排序方式: 共有3215条查询结果,搜索用时 468 毫秒
91.
92.
93.
Martínez-Avilés L Alvarez-Larrán A Besses C Navarro G Torres E Longarón R Angona A Pedro C Florensa L Serrano S Bellosillo B 《Annals of hematology》2012,91(10):1555-1562
JAK2V617F-negative essential thrombocythemia (ET) is a heterogeneous disease including clonal cases and others without evidence of clonality. However, it is unknown if the detection of myeloid clonality in JAK2V617F-negative ET patients confers a different clinical outcome than those in whom clonal hematopoiesis cannot be demonstrated. The objective of the present study was to evaluate the clinical significance of clonality assessment in patients with JAK2V617F-negative ET. Clonality investigation including mutational status of MPL, TET2, and ASXL1 genes and human androgen receptor (HUMARA) assay was performed in 73 JAK2V617F-negative cases out of 186 subjects consecutively diagnosed with ET in a single institution, at diagnosis or during follow-up. Mutations in MPL, TET2, and ASXL1 were observed in 7, 4, and 2 cases, respectively, whereas clonality by HUMARA assay was demonstrated in 21 out of 46 (46?%) female patients. With a median follow-up of 8?years, death, thrombosis, bleeding, and disease transformation were registered in 7, 10, 8, and 6 patients, respectively. No differences in thrombosis, bleeding or survival were observed according to clonality assessment. The probability of disease transformation at 10?years was higher in patients showing clonal hematopoiesis by presenting mutations in either MPL, TET2, or ASXL1 (64 versus 2?% in patients without mutations, p?0.001) and in those with HUMARA clonality (35 versus 0?% in patients with polyclonal hematopoiesis, p?0.004). In conclusion, disease transformation is associated with evidence of clonality in JAK2V617F-negative ET. 相似文献
94.
Odena G Miquel M Serafín A Galan A Morillas R Planas R Bartolí R 《World journal of gastroenterology : WJG》2012,18(17):2084-2091
AIM: To compare rifaximin and insulin-like growth factor (IGF)-1 treatment of hyperammonemia and brain edema in cirrhotic rats with portal occlusion.METHODS: Rats with CCl4-induced cirrhosis with ascites plus portal vein occlusion and controls were randomized into six groups: Cirrhosis; Cirrhosis + IGF-1; Cirrhosis + rifaximin; Controls; Controls + IGF-1; and Controls + rifaximin. An oral glutamine-challenge test was performed, and plasma and cerebral ammonia, glucose, bilirubin, transaminases, endotoxemia, brain water content and ileocecal cultures were measured and liver histology was assessed.RESULTS: Rifaximin treatment significantly reduced bacterial overgrowth and endotoxemia compared with cirrhosis groups, and improved some liver function parameters (bilirubin, alanine aminotransferase and aspartate aminotransferase). These effects were associated with a significant reduction in cerebral water content. Blood and cerebral ammonia levels, and area-under-the-curve values for oral glutamine-challenge tests were similar in rifaximin-treated cirrhotic rats and control group animals. By contrast, IGF-1 administration failed to improve most alterations observed in cirrhosis.CONCLUSION: By reducing gut bacterial overgrowth, only rifaximin was capable of normalizing plasma and brain ammonia and thereby abolishing low-grade brain edema, alterations associated with hepatic encephalopathy. 相似文献
95.
Bai R Di Biase L Mohanty P Dello Russo A Casella M Pelargonio G Themistoclakis S Mohanty S Elayi CS Sanchez J Burkhardt JD Horton R Gallinghouse GJ Bailey SM Bonso A Beheiry S Hongo RH Raviele A Tondo C Natale A 《Journal of cardiovascular electrophysiology》2012,23(2):137-144
MVI Block vs Trigger Ablation in PMFL . Introduction: Patients with previous ablation for atrial fibrillation (AF) may experience recurrence of perimitral flutter (PMFL). These arrhythmias are usually triggered from sources that may also induce AF. This study aims at determining whether ablation of triggers or completing mitral valve isthmus (MVI) block prevents more arrhythmia recurrences. Methods and Results: Sixty‐five patients with recurrent PMFL after initial ablation of long standing persistent AF were included in this study. Thirty‐two patients were randomized to MVI ablation only (Group 1) and 33 were randomized to cardioversion and repeat pulmonary vein (PV) isolation plus ablation of non‐PV triggers (Group 2). MVI bidirectional block was achieved in all but 1 patient from Group 1. In Group 2, reconnection of 17 PVs was detected in 14 patients (42%). With isoproterenol challenge, 44 non‐PV trigger sites were identified in 28 patients (85%, 1.57 sites per patient). At 18‐month follow‐up, 27 patients (84%) from Group 1 had recurrent atrial tachyarrhythmias, of whom 15 remained on antiarrhythmic drug (AAD); however, 28 patients from Group 2 (85%, P < 0.0001 vs Group 1) were free from arrhythmia off AAD. The ablation strategy used in Group 2 was associated with a lower risk of recurrence (hazard ratio = 0.10, 95% CI 0.04–0.28, P < 0.001) and an improved arrhythmia‐free survival (log rank P < 0.0001). Conclusion: In patients presenting with PMFL after ablation for longstanding persistent AF, MVI block had limited impact on arrhythmia recurrence. On the other hand, elimination of all PV and non‐PV triggers achieved higher freedom from atrial arrhythmias at follow‐up. (J Cardiovasc Electrophysiol, Vol. 23, pp. 137‐144, February 2012) 相似文献
96.
Chemokines are a family of low-molecular-weight proteins essential to the directed migration of cells under homeostatic and pathological conditions. Fractalkine (CX3CL1) is an unusual chemokine that can act as either a soluble or membrane-bound mediator and signals through the G protein-coupled chemokine receptor CX3CR1, expressed on monocytes, natural killer cells, T cells, and smooth muscle cells. Accumulating evidence suggests that fractalkine, in addition to its role in chemotaxis and adhesion of leukocytes, supports the survival of multiple cell types during homeostasis and inflammation. This review presents the evidence obtained from several disease models implying an antiapoptotic function for fractalkine and shows how this is relevant to the pathology of atherosclerosis and other vascular diseases. We discuss whether the key role of fractalkine, unlike other chemokines, is the promotion of cell survival and whether this has implications for vascular disease. 相似文献
97.
98.
Battipaglia I Scalone G Macchione A Pinnacchio G Laurito M Milo M Pelargonio G Bencardino G Bellocci F Pieroni M Lanza GA Crea F 《Circulation journal》2012,76(3):618-623
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is associated with an increased risk of sudden cardiac death (SCD). Risk stratification of ARVC/D patients, however, remains an unresolved issue. In this study we investigated whether heart rate variability (HRV) can be helpful in identifying ARVC/D patients with increased risk of arrhythmic events. METHODS AND RESULts: We studied 30 consecutive patients (17 males; 45.4 ± 18 years) with ARVC/D, diagnosed according to guideline criteria; 15 patients (50%) had received an implantable cardioverter defibrillator (ICD) for primary SCD prevention. HRV was assessed on 24-h ECG Holter monitoring. The primary endpoint was the occurrence of major arrhythmic events (SCD, sustained ventricular tachycardia (VT), ICD therapy for sustained VT or ventricular fibrillation (VF)). During the follow-up period (19 ± 7 months), no deaths occurred, but 5 patients (17%) experienced arrhythmic events (4 VTs and 1 VF, all in the ICD group). All HRV parameters were significantly lower in patients with, compared with those without, arrhythmic events. Low-frequency amplitude was the most significant HRV variable associated with arrhythmic events in univariate Cox regression analysis (P=0.017), and was the only significant predictor of arrhythmic events in multivariable regression analysis (hazard ratio 0.88, P=0.047), together with unexplained syncope (hazard ratio 16.1, P=0.039). CONCLUSIONS: Our data show that among ARVC/D patients HRV analysis might be helpful in identifying those with increased risk of major arrhythmic events. 相似文献
99.
Catecholamines (epinephrine and norepinephrine) are synthesised and produced by the adrenal medulla and postganglionic nerve
fibres of the sympathetic nervous system. It is known that essential hypertension has a significant neurogenic component,
with the rise in blood pressure mediated at least in part by overactivity of the sympathetic nervous system. Moreover, novel
therapeutic strategies aimed at reducing sympathetic activity show promise in the treatment of hypertension. This article
reviews recent advances within this rapidly changing field, particularly focusing on the role of genetic polymorphisms within
key catecholamine biosynthetic enzymes, cofactors, and storage molecules. In addition, mechanisms linking the sympathetic
nervous system and other adverse cardiovascular states (obesity, insulin resistance, dyslipidaemia) are discussed, along with
speculation as to how recent scientific advances may lead to the emergence of novel antihypertensive treatments. 相似文献
100.
Ishii T Hagiwara K Ikeda S Arai T Mieno MN Kumasaka T Muramatsu M Sawabe M Gemma A Kida K 《COPD》2012,9(4):409-416
Surfactant protein D (SFTPD) is a lung-specific anti-inflammatory factor that antagonizes inflammation by inhibiting oxidative stress and stimulating innate immunity. Variations in SFTPA2 and SFTPB, genes for other surfactant proteins, have been associated with lung cancer. We therefore investigated associations between SFTPD variations and lung cancer as well as emphysema and interstitial pneumonia, which are characterized by chronic inflammation from which lung cancer often arises. DNA from 1342 autopsy samples, including those from 140 subjects with lung cancer, was investigated. The single nucleotide polymorphism (SNP) rs721917, which results in methionine being exchanged for threonine at amino acid 11 (the Met11Thr variation), tended to be associated with emphysema and was associated with interstitial pneumonia and lung cancer. A haplotype analysis revealed that the haplotypes associated with emphysema and lung cancer differed from that associated with interstitial pneumonia, suggesting a differential role for SFTPD in the development of these diseases. A mediating analysis did not reveal a mediating effect exerted by emphysema or interstitial pneumonia on lung cancer. Our results suggested that SFTPD plays a role in the development of lung cancer and that the role for lung cancer may differ from that for interstitial pneumonia. 相似文献